New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
07:00 EDTAERIAerie Pharmaceuticals shares should be bought ahead of data, says Stifel
After traveling with Aerie's management, Stifel believes there is a good chance that the Phase 2b data for the company's Roclatan will be positive. The firm expects the data to be released in late June/early July, and it recommends buying shares of Aerie ahead of the data release. It keeps a $24 price target and Buy rating on the shares.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
09:09 EDTAERIAerie Pharmaceuticals management to meet with Needham
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use